Caroline Chuard,Fabienne Loetscher,Christian P R Schmid
Caroline Chuard
We investigate whether individuals adjust their health care utilization in anticipation of forthcoming price changes. Leveraging an exogenous increase in cost-sharing in the Swiss health care system at the age of 18, we estimate the impact ...
Wynand P M M van de Ven
Wynand P M M van de Ven
Many countries with a competitive health insurance market have implemented a risk equalization system with health-based risk adjusters. An often-heard argument is that health-based equalization payments create a penalty on prevention and he...
Differentiation of morbidity measurement in Germany's morbidity-based risk adjustment depending on general practitioner and specialist treatment [0.03%]
基于德国以疾病为基础的风险调整机制下根据全科和专科治疗区分疾病负担的测量指标的区别化考核
Christian Keutel,Florian Renker,Marco Papatrifon et al.
Christian Keutel et al.
Morbidity-based risk adjustment schemes are of central importance to prevent incentives for risk selection and to ensure fair competition in health insurance systems with regulated competition, including in Germany. However, systematic unde...
Francesco Colcerasa,Fabio Pisani
Francesco Colcerasa
We contribute to the literature on subjective well-being by examining the relationship between life satisfaction and health inequalities, focusing on both inequality in outcomes and inequality of opportunity. The role of the latter is teste...
Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 2023 [0.03%]
2020至2023年欧盟28国过量死亡和新冠肺炎死亡导致的有酬与无酬生产力损失估算
Paweł Niewiadomski,Marta Ortega-Ortega,Błażej Łyszczarz
Paweł Niewiadomski
Cancer specific health utilities - QLU-C10D country value sets for Belgium, Hungary, Portugal and the Republic of Korea - an international valuation study [0.03%]
针对癌症的健康效用值——QLU-C10D国家赋值集：比利时、匈牙利、葡萄牙和大韩民国的结果——一项国际合作研究
Micha J Pilz,Georg Kemmler,Jonas Dreher et al.
Micha J Pilz et al.
Is EQ-5D-5L better than EQ-5D-3L? A comparison of descriptive systems and utility scores in patients with kidney chronic disease [0.03%]
EQ-5D-5L较EQ-5D-3L优吗？慢性肾病患者中描述系统和效用值的比较研究
Carmen Selva-Sevilla,Agustín Ortega-Cerrato,Juan Pérez-Martínez et al.
Carmen Selva-Sevilla et al.
Price development of orphan drugs in Germany after market access and subsequent assessments: a descriptive analysis [0.03%]
德国孤儿药市场准入及后续评估的价格变化：描述性分析
C Balg,K Frangen,A C Brockhaus et al.
C Balg et al.
The add-on list cannot do it all: a comparative economic evaluation of equity impacts in the German and French inpatient care sectors [0.03%]
扩充清单无法包罗一切：德国和法国住院医疗部门经济公平影响的比较评价研究
Mira Hartmann,Baptiste Haon,Lise Rochaix et al.
Mira Hartmann et al.